RegulationOrphan Drug (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union), Regenerative Medicine Advanced Therapy (United States), Advanced Therapy Medicinal Products (European Union), Priority Review (United States)

Clinical Trials associated with Deramiocel

NCT05126758

/ Active, not recruitingPhase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy

HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a cell therapy called deramiocel (CAP-1002) in study participants with Duchenne muscular dystrophy (DMD) and impaired skeletal muscle function. Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either deramiocel or placebo every 3 months for a total of 4 doses during the first 12 months of the study. All participants will be eligible to receive 4 doses of deramiocel for an additional 12 months as part of an open-label extended assessment period. After completion of the first open-label extension (Months 12-24), subjects who have completed Month 24 are eligible to continue onto a Long-Term Open-Label Extension period that will provide treatment with deramiocel until commercial availability, or until sponsor's decision to terminate the trial, or the participant withdraws consent.

Start Date22 Jun 2022

Sponsor / Collaborator

Capricor, Inc.

NCT04623671

/ CompletedPhase 2

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 in Patients With COVID-19 (INSPIRE)

This is a randomized, double-blind, placebo-controlled, Pilot, Phase 2 Exploratory study that will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing and who are in severe or critical condition as indicated by life-support measures.

Start Date15 Nov 2020

Sponsor / Collaborator

Capricor, Inc.

NCT04428476

/ Active, not recruitingPhase 2

Open-Label Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial

This Phase 2, multi-center, open-label extension trial will provide deramiocel (CAP-1002) to subjects that were enrolled in the HOPE-2 trial and completed 12 months of follow-up. The trial will explore the safety and efficacy of twenty intravenous administrations of deramiocel, each separated by three months, over a period of approximately 60 months. Following completion of the initial open-label phase (Month 60), subjects who have completed all Month 60 assessments will be eligible to continue into a long-term open label extension (LT-OLE) period and can continue to receive deramiocel once every 3 months until deramiocel is commercially available or the sponsor terminates the study, or the subject withdraws consent or study participation is terminated by the sponsor.
Subjects will undergo a targeted screening during a 30-day screening period, eligible subjects will then undergo baseline safety and efficacy assessments on Day 1 prior to their first infusion of deramiocel.
Subjects will complete trial assessments at Screening; Day 1; Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, and all LT-OLE visits. Safety and efficacy assessments will be conducted prior to deramiocel administration at the Day 1, Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, and at all LT-OLE trial visits, unless otherwise indicated.
All deramiocel infusions will be conducted in an outpatient setting at the investigative site on Day 1 and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, with continued dosing in the LT-OLE visits. Subjects will be observed in the outpatient setting for at least two hours post infusion and then discharged the same day, if medically cleared by the site Investigator.

Start Date05 Aug 2020

Sponsor / Collaborator

Capricor, Inc.

100 Clinical Results associated with Deramiocel

100 Translational Medicine associated with Deramiocel

100 Patents (Medical) associated with Deramiocel

Literatures (Medical) associated with Deramiocel

02 Jan 2023·Expert opinion on biological therapy

Biological and genetic therapies for the treatment of Duchenne muscular dystrophy

Review

Author: Wilton-Clark, Harry ; Yokota, Toshifumi

INTRODUCTION:

Duchenne muscular dystrophy is a lethal genetic disease which currently has no cure, and poor standard treatment options largely focused on symptom relief. The development of multiple biological and genetic therapies is underway across various stages of clinical progress which could markedly affect how DMD patients are treated in the future.

AREAS COVERED:

The purpose of this review is to provide an introduction to the different therapeutic modalities currently being studied, as well as a brief description of their progress to date and relative advantages and disadvantages for the treatment of DMD. This review discusses exon skipping therapy, microdystrophin therapy, stop codon readthrough therapy, CRISPR-based gene editing, cell-based therapy, and utrophin upregulation. Secondary therapies addressing nonspecific symptoms of DMD were excluded.

EXPERT OPINION:

Despite the vast potential held by gene replacement therapy options such as microdystrophin production and utrophin upregulation, safety risks inherent to the adeno-associated virus delivery vector might hamper the clinical viability of these approaches until further improvements can be made. Of the mutation-specific therapies, exon skipping therapy remains the most extensively validated and explored option, and the cell-based CAP-1002 therapy may prove to be a suitable adjunct therapy filling the urgent need for cardiac-specific therapies.

01 Mar 2022·Lancet (London, England)Q1 · MEDICINE

Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Q1 · MEDICINE

Article

Author: Collado, Jorge ; Johnson, Hannah ; Harmelink, Matthew M ; Connolly, Anne ; Muntoni, Francesco ; Furlong, Pat ; Anderson, Kristan ; Newton, Andrew ; Abedi, Mehrdad ; Dayan, Jonathan G. ; Pyzik, Erika ; Ruckdeschel Smith, Rachel ; Marbán, Linda ; Hor, Kan N ; Williams, Paula ; Varadhachary, Arun S ; Ascheim, Deborah D ; Jhawar, Sanjay ; Prasad, Poonam ; Chouteau, Wendy ; Finkel, Richard S ; Hendrix, Suzanne ; Kusmik, Kyle ; Janas, Joanne ; Wells, Julie ; Sarwary, Omaid ; Brown, Michelle ; Eagle, Michelle ; Surampudi, Prasanth ; Van Eyk, Jennifer ; Joyce, Nanette C. ; Giordano, Anthony F. ; Filar, Lauri ; Goude, Erica ; Butterfield, Russell ; Rybalsky, Irina ; McDonald, Craig M ; Anthonisen, Colleen ; Taylor, Michael D ; Rehborg, Rebecca ; Civitello, Matthew ; Wezel, Germaine ; Tian, Cuixia ; Duke, Julie ; Baek, Jayoon ; Marbán, Eduardo ; Henricson, Erik K ; Rogers, Russell G. ; Edmondson, Angie ; Vega, Melisa ; Rodriguez, Aixa ; Nicorici, Alina ; Mayer, Oscar H ; Evans, Maya ; Hogan, Nathaniel ; Rogy, Siegfried

BACKGROUND:

Cardiosphere-derived cells (CDCs) ameliorate skeletal and cardiac muscle deterioration in experimental models of Duchenne muscular dystrophy. The HOPE-2 trial examined the safety and efficacy of sequential intravenous infusions of human allogeneic CDCs in late-stage Duchenne muscular dystrophy.

METHODS:

In this multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, patients with Duchenne muscular dystrophy, aged 10 years or older with moderate upper limb impairment, were enrolled at seven centres in the USA. Patients were randomly assigned (1:1) using stratified permuted blocks to receive CAP-1002 (1·5 × 10⁸ CDCs) or placebo intravenously every 3 months for a total of four infusions. Clinicians, caregivers, patients, and clinical operations personnel were fully masked to treatment groups. The primary outcome was the change in mid-level elbow Performance of Upper Limb version 1.2 (PUL 1.2) score at 12 months, assessed in the intention-to-treat population. Safety was assessed in all individuals who received an investigational product. This trial is registered with ClinicalTrials.gov, NCT03406780.

FINDINGS:

Between March 1, 2018, and March 31, 2020, 26 male patients with Duchenne muscular dystrophy were enrolled, of whom eight were randomly assigned to the CAP-1002 group and 12 to the placebo group (six were not randomised due to screening failure). In patients who had a post-treatment PUL 1.2 assessment (eight in the CAP-1002 group and 11 in the placebo group), the mean 12-month change from baseline in mid-level elbow PUL1.2 favoured CAP-1002 over placebo (percentile difference 36·2, 95% CI 12·7-59·7; difference of 2·6 points; p=0·014). Infusion-related hypersensitivity reactions without long-term sequelae were observed in three patients, with one patient discontinuing therapy due to a severe allergic reaction. No other major adverse reactions were noted, and no deaths occurred.

INTERPRETATION:

CAP-1002 cell therapy appears to be safe and effective in reducing deterioration of upper limb function in patients with late-stage Duchenne muscular dystrophy. Various measures of cardiac function and structure were also improved in the CAP-1002 group compared with the placebo group. Longer-term extension studies are needed to confirm the therapeutic durability and safety of CAP-1002 beyond 12 months for the treatment of skeletal myopathy and cardiomyopathy in Duchenne muscular dystrophy.

FUNDING:

Capricor Therapeutics.

01 Jul 2020·Basic research in cardiology

Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series

Article

Author: Friedman, Oren ; Chen, Peter ; Marbán, Linda ; Singh, Siddharth ; Akhmerov, Akbarshakh ; Zaman, Tanzira ; Falk, Jeremy ; Ebinger, Joseph E ; Marbán, Eduardo ; Gheorghiu, Mitch ; Makkar, Raj R ; Chakravarty, Tarun

Abstract:

There are no definitive therapies for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Therefore, new therapeutic strategies are needed to improve clinical outcomes, particularly in patients with severe disease. This case series explores the safety and effectiveness of intravenous allogeneic cardiosphere-derived cells (CDCs), formulated as CAP-1002, in critically ill patients with confirmed coronavirus disease 2019 (COVID-19). Adverse reactions to CAP-1002, clinical status on the World Health Organization (WHO) ordinal scale, and changes in pro-inflammatory biomarkers and leukocyte counts were analyzed. All patients (n = 6; age range 19–75 years, 1 female) required ventilatory support (invasive mechanical ventilation, n = 5) with PaO2/FiO2 ranging from 69 to 198. No adverse events related to CAP-1002 administration were observed. Four patients (67%) were weaned from respiratory support and discharged from the hospital. One patient remains mechanically ventilated as of April 28th, 2020; all survive. A contemporaneous control group of critically ill COVID-19 patients (n = 34) at our institution showed 18% overall mortality at a similar stage of hospitalization. Ferritin was elevated in all patients at baseline (range of all patients 605.43–2991.52 ng/ml) and decreased in 5/6 patients (range of all patients 252.89–1029.90 ng/ml). Absolute lymphocyte counts were low in 5/6 patients at baseline (range 0.26–0.82 × 103/µl) but had increased in three of these five patients at last follow-up (range 0.23–1.02 × 103/µl). In this series of six critically ill COVID-19 patients, intravenous infusion of CAP-1002 was well tolerated and associated with resolution of critical illness in 4 patients. This series demonstrates the apparent safety of CAP-1002 in COVID-19. While this initial experience is promising, efficacy will need to be further assessed in a randomized controlled trial.

156

News (Medical) associated with Deramiocel

08 Dec 2025

·www.fiercebiotech.com

Dyne readies FDA push after DMD exon 51 med excels in trial

With new data in hand, Dyne Therapeutics is eyeing an approval filing next year and a potential launch in early 2027.\n Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy (DMD), a challenger from Massachusetts biotech Dyne Therapeutics is moving toward a regulatory filing on the heels of a trial win.Dyne’s phase 1/2 Deliver study enrolled 86 patients with DMD amenable to 51 skipping, who make up about 13% of the overall DMD patient population, according to a Dec. 8 company presentation.In the registrational expansion cohort of the study, which comprised 32 patients, patients treated with 20 mg/kg of z-rostudirsen every four weeks experienced a statistically significant change from baseline in muscle-content adjusted dystrophin expression, the biotech said in a press release. In the group, 24 patients received the therapy and eight received placebo.After six months, patients treated with the drug reached mean absolute dystrophin expression of 5.46% of normal levels, when adjusting for muscle content. The unadjusted number was 2.87%, the company said.While cross-trial comparisons are imperfect for various reasons, a clinical trial of Sarepta’s Exondys 51 showed that patients who received the weekly drug reached 0.3% of normal dystrophin levels, Dyne pointed out.As for functional endpoints, Dyne touted “improvement relative to placebo” across six measures such as time to rise, 10-meter walk/run velocity and lung function.The drug “has the potential to transform the care of those living with DMD amenable to exon 51 skipping,” Dyne CEO John Cox said in a statement, describing the data as “unprecedented.“ The company plans to submit an application for accelerated FDA approval in the second quarter of next year. A launch in early 2027 could follow, the CEO added. The company is eyeing a market of 1,600 individuals in the U.S. who have “significant unmet need,“ according to Cox.Dyne further touted a “favorable” safety and tolerability profile, noting that most treatment-emergent adverse events (TEAEs) were mild or moderate. The most common TEAEs were fever and headache. No related serious TEAEs were seen in the registrational cohort, the biotech said.Dyne isn’t waiting for a potential approval to build out its team, with Cox noting that the biotech has added medical, commercial and CMC experts “to enable a capital efficient and successful launch.”In a note to clients Monday, Evercore ISI analyst Gavin Clark-Gartner wrote that the results meet the bar for an accelerated approval. The analyst is modeling 75% to 80% chances of approval for the product, plus $700 million in potential peak sales, mostly driven by switches from Sarepta’s rival offering.After the data drop and an investor presentation Monday, Dyne’s shares were trading up about 15% at $23.34 apiece.In addition to the planned regulatory interactions, Dyne says it’s looking to start a phase 3 trial next year “to support global approvals.” The trial readout comes right on the heels of Capricor Therapeutics\' DMD cell therapy triumph with deramiocel. Among patients enrolled in the Hope-3 trial, those given deramiocel every three months for a year experienced significantly slower deterioration in upper limb function compared to those given placebo, the biotech said last week.Sarepta, for its part, had planned to introduce its own successor to Exondys 51 but axed a follow-up candidate last year due to a safety signal.

Clinical ResultDrug ApprovalCell TherapyClinical StudyAccelerated Approval

05 Dec 2025

·www.globenewswire.com

Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $25.00 per share. Capricor also granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about December 8, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be $150 million, before deducting underwriting discounts and commissions and offering expenses payable by Capricor and assuming no exercise of the underwriters' option to purchase additional shares. Piper Sandler and Oppenheimer & Co. are acting as the joint book-running managers for the public offering. H.C. Wainwright & Co. is acting as the co-manager for the public offering. The Company intends to use the net proceeds from the offering for the continued development of its product candidates, manufacturing of its product candidates, working capital and general corporate purposes. The securities are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-290179) that was originally filed with the Securities and Exchange Commission (“SEC”) on September 10, 2025 and declared effective on September 23, 2025. The offering is being made only by means of a prospectus and related prospectus supplement. A preliminary prospectus supplement relating to the offering was filed with the SEC on December 4, 2025. The final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. When available, electronic copies of the prospectus supplement and the accompanying prospectus may also be obtained from Piper Sandler & Co. at 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at prospectus@psc.com; and Oppenheimer & Co. Inc. at Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, by telephone at (212) 667-8055 or by email at EquityProspectus@opco.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Capricor Therapeutics Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, Deramiocel, an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for the treatment of Duchenne muscular dystrophy (DMD). Extensive preclinical and clinical data have demonstrated Deramiocel’s potent immunomodulatory and anti-fibrotic effects in helping to preserve cardiac and skeletal muscle function in DMD. Capricor is also leveraging the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on vaccinology and the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics, with the potential to treat and prevent a wide range of diseases. At Capricor, we are committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. Cautionary Note Regarding Forward-Looking Statements Statements in this press release regarding the timing and completion of the public offering of common stock and the anticipated use of proceeds therefrom and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including, but not limited to, risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the offering. There can be no assurance that Capricor will be able to complete the public offering on the anticipated terms, or at all. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 26, 2025, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as filed with the Securities and Exchange Commission on November 10, 2025. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements. Capricor has entered into an agreement for the exclusive commercialization and distribution of Deramiocel for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel and the StealthX™ vaccine are investigational candidates and have not been approved for commercial use in any indication. For more information, please contact: Capricor Media Contact:Raquel ConaKCSA Strategic Communicationsrcona@kcsa.com212.896.1204 Capricor Company Contact:AJ Bergmann, Chief Financial Officerabergmann@capricor.com858.727.1755 Source: Capricor Therapeutics

VaccineClinical StudyCell Therapy

03 Dec 2025

·www.fiercebiotech.com

Capricor\'s phase 3 win sets up 2nd approval attempt for Duchenne cell therapy

Capricor’s stock soared on the news, shooting up from $6.36 per share at the prior day’s close to a high of $40.37.\n Capricor Therapeutics has notched a key win in its efforts to bring its Duchenne muscular dystrophy cell therapy, deramiocel, to market, hitting the primary endpoint in a phase 3 trial.In 105 boys and young men enrolled in the HOPE-3 trial, patients given deramiocel every three months for a year had 54% slower deterioration in upper limb function compared to placebo, Capricor announced in a Dec. 3 release, achieving the study’s main goal.In the key secondary endpoint of left ventricular ejection fraction, a measure of heart function, deramiocel bested placebo with a 91% slowing of disease progression in 83 patients, Capricor said. Both measures were statistically significant. Treatment reflected a safety profile similar to past studies of deramiocel, the biotech added. The cell therapy consists of donor-derived cardiac cells called cardiosphere-derived cells, which are meant to reprogram macrophages to combat inflammation.Capricor’s stock soared on the news, shooting up from $6.36 per share at Tuesday\'s market close to a high of $40.37. As of 10:50 a.m. ET on Dec. 3, the share price has settled at $25.56, an increase from yesterday of about 300%. San Diego-based Capricor submitted a biologics license application for deramiocel last year on the back of data from a phase 2 study and open-label extension, which similarly showed that the therapy improved patients’ upper limb and heart function.But despite the FDA previously okaying Capricor’s study designs, the company said, the drug regulator rejected deramiocel in July, and later made its complete response letter (CRL) public in September as part of a new initiative to release CRLs as they are issued to sponsors.“We believe these pivotal study results, in addition to the evidence from the HOPE-2 and HOPE-2 OLE studies, position us to address the clinical issues in the complete response letter received earlier this year, consistent with prior FDA guidance that HOPE-3 results should be sufficient to support regulatory approval,” Capricor CEO Linda Marbán, Ph.D., said in the release.Capricor now plans to submit its response to the CRL, with the topline HOPE-3 data included, according to the release.In rejecting deramiocel, the FDA said that the phase 2 trial “failed to demonstrate efficacy for its prespecified primary efficacy endpoint.” Capricor responded that the endpoint actually was met if the proper statistical test was used to analyze the data.

Phase 3Cell TherapyPhase 2Clinical Result

100 Deals associated with Deramiocel

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Muscular Dystrophy, Duchenne	NDA/BLA	United States	Capricor Therapeutics, Inc.	09 Oct 2024
COVID-19	Phase 2	United States	Capricor, Inc.	15 Nov 2020
Heart failure with normal ejection fraction	Phase 2	United States	The Medical University of South Carolina	12 Jul 2017
Heart Failure, Diastolic	Phase 2	United States	The Medical University of South Carolina	12 Jul 2017
Cardiomyopathies	Phase 2	United States	Capricor, Inc.	07 Jan 2016
Tabes Dorsalis	Phase 2	United States	Capricor, Inc.	07 Jan 2016
Non-St Elevated Myocardial Infarction	Phase 2	United States	Capricor, Inc.	13 Nov 2012
ST Elevation Myocardial Infarction	Phase 2	United States	Capricor, Inc.	13 Nov 2012
Ventricular Dysfunction, Left	Phase 2	United States	Capricor, Inc.	13 Nov 2012
Cardiomyopathy, Dilated	Phase 1	United States	Capricor, Inc.	01 Nov 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05126758 (HOPE-3, GlobeNewswire) Manual	Phase 3	Muscular Dystrophy, Duchenne	106	Deramiocel	nhyrbhclox(dgykdzkjqm) = vhopuirstl ucuddjmtsz (rvzgwxrehg ) Met View more	Positive	03 Dec 2025
				Placebo	-
NCT04428476 (HOPE-2-OLE, GlobeNewswire) Manual	Phase 2	Muscular Dystrophy, Duchenne	-	Deramiocel	fkrsmmumpk(fscapdhvol) = jfnaqdcozp skpmttunjt (qiebrxteyl )	Positive	17 Mar 2025
				External Comparator Group	fkrsmmumpk(fscapdhvol) = fynliptuhk skpmttunjt (qiebrxteyl )
NCT03406780 (HOPE-2, CTgov)	Phase 2	Muscular Dystrophy, Duchenne	20	CAP-1002 (CAP-1002)	evlprqlwqt(famzammrwu) = xccqgxqoin qfgkmwljnu (cbzsautswc, 10.82) View more	-	24 Feb 2025
				Placebo (Placebo)	evlprqlwqt(famzammrwu) = gngkpcksxh qfgkmwljnu (cbzsautswc, 9.23) View more
NCT04428476 (HOPE-2 OLE \| HOPE-2-OLE, CTgov)	Phase 2	Muscular Dystrophy, Duchenne	13	CAP-1002	ndkihziucs = zwdqjtxkya inaetduwzn (ppqimfpknv, jmxvtvnytb - lbejcuxach) View more	-	24 Feb 2025
NCT04623671 (INSPIRE, CTgov)	Phase 2	COVID-19	55	CAP-1002 (CAP-1002)	imtjdbqomf = lxheqeksla gvldcbdgvl (kxbigksach, ybkmkwqdpa - trnxqgguip) View more	-	20 Feb 2025
				Placebo (Placebo)	imtjdbqomf = wbwmzcwkmx gvldcbdgvl (kxbigksach, mrezrlckdc - aizwibjxao) View more
NCT04428476 (HOPE-2 OLE, GlobeNewswire) Manual	Phase 2	Muscular Dystrophy, Duchenne	-	Deramiocel	fpkirklwmn(sdwqqmlurs) = uhjbvklrlc azsbdbmpga (lfmtewlxoy )	Positive	11 Oct 2024
NCT02941705 (RegressHFpEF, CTgov)	Phase 2	Heart failure with normal ejection fraction \| Heart Failure, Diastolic	27	Allogeneic Derived Cells (RECIEVED CELLS)	bgrgvfyxlw = fthvhyvfpt fbytqghpgt (lzfmmyenlc, gbhzgnkqdc - bdixgumsas) View more	-	25 Jul 2024
				Placebo/Control Arm (CONTROL ARM)	bgrgvfyxlw = pooevzpryf fbytqghpgt (lzfmmyenlc, pwxcjaxwts - uyeukjkjra) View more
NCT04428476 (HOPE-2-OLE, Biospace) Manual	Phase 2	Muscular Dystrophy, Duchenne	20	CAP-1002	qhrfcqtxjb(bmcgntfwjn) = vqpwdfccvp xqufczuzzx (nqdhystfqd )	Positive	04 Jun 2024
				External Comparator	qhrfcqtxjb(bmcgntfwjn) = clcavomrxd xqufczuzzx (nqdhystfqd )
NCT06304064 (HOPE-OLE \| CAP-1002-DMD-03, CTgov)	Phase 2	Muscular Dystrophy, Duchenne	8	CAP-1002	bpfahegaba = oobzwvgpaw ikvkkmgtaf (uyrbwiqudv, kggmfmrhsi - jjksomjbcf) View more	-	24 Apr 2024
NCT01458405 (ALLSTAR, CTgov)	Phase 1/2	Ventricular Dysfunction, Left \| Myocardial Infarction \| Non-St Elevated Myocardial Infarction ... View more	135	placebo (Randomized Treatment Cohort: Placebo)	lifllkdkzp = ygoaprkuof rdcbkipspm (irlrpmkjny, ozuqatlrud - lwdttamnht) View more	-	09 Apr 2024
				CAP-1002 (Randomized Treatment Cohort: CAP-1002 Allogeneic Cardiosphere-Derived Cells)	lifllkdkzp = qowwjukqfr rdcbkipspm (irlrpmkjny, vikokckvpi - xqzeisacjm) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Deramiocel

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation